Pro: Urine proteomics as a liquid kidney biopsy: no more kidney punctures!
- 23 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (4) , 532-537
Abstract
In this article, the benefits of urinary proteomics in comparison with kidney biopsy are discussed. The majority of urinary proteins are generated by the kidney, hence the urinary proteome holds substantial information on the kidney, and assessment of the urinary proteome could be considered a ‘liquid biopsy’. The main question is how well the information contained in the urinary proteome can be assessed today, if it is ready to be routinely used, and what are the advantages and possible disadvantages in comparison with current standards. Since chronic kidney disease (CKD) is by far the largest area in nephrology based on the number of patients affected, the focus of this article is on CKD. Substantial progress was made in the last decade in urinary proteomics, and today we have comparable urinary proteome datasets of tens of thousands of subjects available. Clinical proteomics studies in CKD including close to, or even exceeding, 1000 subjects have recently been published, demonstrating a benefit over the current state-of-the-art in diagnosis and especially prognosis. The first large multicentric randomized controlled intervention trial aiming at preventing CKD by employing urinary proteomics-guided intervention has been initiated recently. These data provide ample evidence for the utility and value of urinary proteomics in nephrology. A further consideration is that the purpose of the biopsy, be it ‘liquid’ or ‘solid’, is to guide intervention. However, essentially all drug targets are proteins, not microscopic structures. Therefore, obtaining information on the proteome to guide intervention appears to be the most appropriate approach. Presenting more detailed evidence, I argue that urinary proteome analysis can, in most cases, be employed to guide therapeutic intervention, can be repeated multiple times as it is without any direct risk or discomfort and can be considered as a liquid biopsy.Keywords
This publication has 27 references indexed in Scilit:
- CKD273, a New Proteomics Classifier Assessing CKD and Its PrognosisPLOS ONE, 2013
- Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applicationsElectrophoresis, 2013
- Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic ProfilesPLOS ONE, 2012
- Safety and Complications of Percutaneous Kidney Biopsies in 715 Children and 8573 Adults in Norway 1988–2010Clinical Journal of the American Society of Nephrology, 2012
- Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaBMC Nephrology, 2010
- Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney DiseaseMolecular & Cellular Proteomics, 2010
- Comprehensive human urine standards for comparability and standardization in clinical proteome analysisProteomics – Clinical Applications, 2010
- Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated VasculitisMolecular & Cellular Proteomics, 2009
- Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and MicroalbuminuriaJournal of the American Society of Nephrology, 2009
- Urinary Proteomics in Diabetes and CKDJournal of the American Society of Nephrology, 2008